Taiwanese Dermatological Association consensus for the prevention and management of epidermal growth factor receptor tyrosine kinase inhibitor-related skin toxicities

被引:29
|
作者
Chu, Chia-Yu [1 ,2 ]
Chen, Kuan-Yu [2 ,3 ]
Chang, John Wen-Cheng [4 ]
Wei, Yu-Feng [5 ,6 ]
Lee, Chih-Hung [7 ,8 ]
Wang, Wei-Ming [9 ,10 ]
机构
[1] Natl Taiwan Univ Hosp, Dept Dermatol, 7 Chung Shan South Rd, Taipei 10002, Taiwan
[2] Natl Taiwan Univ, Coll Med, 7 Chung Shan South Rd, Taipei 10002, Taiwan
[3] Natl Taiwan Univ Hosp, Dept Internal Med, Taipei, Taiwan
[4] Chang Gung Univ, Chang Gung Mem Hosp Linkou, Coll Med, Dept Internal Med,Div Hematol Oncol, Taoyuan, Taiwan
[5] I Shou Univ, Dept Internal Med, Kaohsiung, Taiwan
[6] E Da Hosp, Kaohsiung, Taiwan
[7] Kaohsiung Chang Gung Mem Hosp, Dept Dermatol, Kaohsiung, Taiwan
[8] Chang Gung Univ, Coll Med, Taoyuan, Taiwan
[9] Triserv Gen Hosp, Dept Dermatol, Taipei, Taiwan
[10] Natl Def Med Ctr, Taipei, Taiwan
关键词
consensus; diagnosis; epidermal growth factor receptor; skin toxicities; tyrosine kinase inhibitors; CELL LUNG-CANCER; OPEN-LABEL; 1ST-LINE TREATMENT; ADVERSE EVENTS; PHASE-III; CARBOPLATIN-PACLITAXEL; CUTANEOUS TOXICITIES; TREATMENT STRATEGIES; GEFITINIB; ERLOTINIB;
D O I
10.1016/j.jfma.2017.03.001
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background/Purpose: This report describes the 2016 consensus of the Taiwanese Dermatological Association (TDA) regarding the definition, classification, diagnosis, prevention, and management of skin toxicities resulting from treatment with epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs). This consensus is distributed to practices throughout Taiwan to provide recommendations for the diagnosis and treatment of such skin toxicities in order to improve the quality of life of patients undergoing EGFR-TKI treatment. The consensus thus serves as an important reference for dermatologists and other interested clinicians, such as oncologists, throughout Taiwan. Methods: All the consensus contents were voted on by the participating experts, with approval by no less than 75% required for inclusion. Results: The consensus provides a comprehensive overview of EGFR-TKI skin toxicities, including recent advances in identifying their causes and the processes by which they develop. Conclusion: All the consensus meeting attendees agreed that there are several major EGFR-TKI-related skin toxicities, including acneiform rash (i.e., papulopustular rash), xeroderma, pruritus, paronychia, stomatitis, mucositis, and hair changes (such as hair loss, slowed hair growth, and trichomegaly). The experts were also generally unanimous in their voting on the specific definitions, onset times, and care suggestions for each of those skin toxicities. Furthermore, the recommended treatment algorithms for the various skin toxicities were ultimately approved by 100% (15/15) of the consensus attendees. Copyright (C) 2017, Formosan Medical Association. Published by Elsevier Taiwan LLC.
引用
收藏
页码:413 / 423
页数:11
相关论文
共 50 条
  • [1] Management of epidermal growth factor receptor tyrosine kinase inhibitor-related cutaneous and gastrointestinal toxicities
    Aw, Derrick Chen-Wee
    Tan, Eng Huat
    Chin, Tan Min
    Lim, Hong Liang
    Lee, Haur Yueh
    Soo, Ross A.
    ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2018, 14 (01) : 23 - 31
  • [2] Management of epidermal growth factor receptor (EGFR) inhibitor-related skin toxicities across Europe
    Lemmens, L.
    EUROPEAN JOURNAL OF ONCOLOGY NURSING, 2010, 14 : S60 - S61
  • [3] Epidermal growth factor receptor inhibitor-related folliculitis
    Tangri, Navdeep
    Al Hammadi, Anwar
    Gerstein, William
    DERMATITIS, 2007, 18 (03) : 178 - 179
  • [4] Specific inhibitor of the epidermal growth factor receptor tyrosine kinase
    Fry, D.W.
    Kraker, A.J.
    McMichael, A.
    Ambroso, L.A.
    Nelson, J.M.
    Leopold, W.R.
    Connors, R.W.
    Bridges, A.J.
    Science, 1994, 265 (5175)
  • [5] Clinical presentation and management of dermatological toxicities of epidermal growth factor receptor inhibitors
    Balagula, Yevgeniy
    Garbe, Claus
    Myskowski, Patricia L.
    Hauschild, Axel
    Rapoport, Bernardo L.
    Boers-Doets, Christine B.
    Lacouture, Mario E.
    INTERNATIONAL JOURNAL OF DERMATOLOGY, 2011, 50 (02) : 129 - 146
  • [6] A real-world analysis of tyrosine receptor kinase inhibitor-related toxicities in cancer treatment
    Li, Wenjie
    Wen, Keshan
    Zhu, Weijie
    Luo, Shangfei
    PERSONALIZED MEDICINE, 2023, 20 (06) : 485 - 491
  • [7] The Epidermal Growth Factor Receptor Inhibitor-Related Skin Toxicity Index (EGFRISTI): A New Tool for Grading and Managing Skin Adverse Reactions to Epidermal Growth Factor Receptor Inhibitors
    Lisi, Paolo
    Bellini, Veronica
    Bianchi, Leonardo
    ONCOLOGY, 2014, 87 (05) : 311 - 319
  • [8] Management of dermatologic toxicities related to epidermal growth factor receptor inhibitor therapy across Europe: can we get a consensus?
    Lemmens, L.
    ECANCERMEDICALSCIENCE, 2011, 5
  • [9] Association of Antibiotic Resistance With Antibiotic Use for Epidermal Growth Factor Receptor Inhibitor-Related Papulopustular Eruption
    Hirotsu, Kelsey
    Dang, Timothy M.
    Li, Shufeng
    Neal, Joel W.
    Pugliese, Silvina
    Subramanian, Aruna
    Kwong, Bernice Y.
    JAMA DERMATOLOGY, 2019, 155 (07) : 848 - 850
  • [10] A SPECIFIC INHIBITOR OF THE EPIDERMAL GROWTH-FACTOR RECEPTOR TYROSINE KINASE
    FRY, DW
    KRAKER, AJ
    MCMICHAEL, A
    AMBROSO, LA
    NELSON, JM
    LEOPOLD, WR
    CONNERS, RW
    BRIDGES, AJ
    SCIENCE, 1994, 265 (5175) : 1093 - 1095